As of now, PD-1 inhibitors have not received approval for first-line systemic therapy in biliary tract cancers, except for Pembrolizumab, which is indicated for mismatch repair-deficient (dMMR) or high microsatellite instability (MSI) tumors. This evidence concerns the gene PDCD1 and biliary tract cancer.